Is IL-23 the Winner? Lessons from Inflammatory Bowel Disease (IBD) and Psoriasis (PsO)
DOI:
https://doi.org/10.58931/cibdt.2025.3348Abstract
Key Takeaways
• Interleukin-23 (IL-23), and the IL-23/Th-17 interaction, plays a pivotal role in the pathogenesis of immune‑mediated diseases, such as psoriasis (PsO) and inflammatory bowel disease (IBD). This has led to the development and commercialization of several anti-IL-23 therapies, all demonstrating high efficacy and safety in the management of these conditions.
• Anti-IL-23 therapies, have been shown to be amongst the most highly effective treatments in PsO, achieving meaningful and durable treatment response (PASI-90) in over 80 per cent of participants in registrational clinical trials, while in IBD the meaningful one-year efficacy, based on the varied definitions of the studies’ primary endpoints, is achieved (at most) in just over 50 per cent of participants, though rates of achieving remission in Crohn’s disease are much lower.
• Several ongoing studies examining the role of IL-23 inhibition in specific IBD populations (ex. perianal Crohn’s disease), and studies examining the combination of IL-23 inhibitors with other targeted therapies, capitalizes on the excellent safety and efficacy profile of anti-IL-23, reflecting the long-term importance of these therapies in the IBD treatment landscape.
References
Jairath V, Acosta Felquer ML, Cho RJ. IL-23 inhibition for chronic inflammatory disease. Lancet. 2024;404(10463):1679–1692. doi:10.1016/S0140-6736(24)01750-1 DOI: https://doi.org/10.1016/S0140-6736(24)01750-1
García-Domínguez, M. The role of IL-23 in the development of inflammatory diseases. Biology (Basel). 2025;14(4):347. Published 2025 Mar 27. doi:10.3390/biology14040347 DOI: https://doi.org/10.3390/biology14040347
Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111(6):1053–1057. doi:10.1046/j.1523-1747.1998.00446.x DOI: https://doi.org/10.1046/j.1523-1747.1998.00446.x
Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–1463. doi:10.1126/science.1135245 DOI: https://doi.org/10.1126/science.1135245
Nakamura M, Lee K, Jeon C, Sekhon S, Afifi L, Yan D, et al. Guselkumab for the treatment of psoriasis: a review of phase iii trials. Dermatol Ther (Heidelb). 2017;7(3):281-292. doi:10.1007/s13555-017-0187-0 DOI: https://doi.org/10.1007/s13555-017-0187-0
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661. doi:10.1016/S0140-6736(18)31713-6 DOI: https://doi.org/10.1016/S0140-6736(18)31713-6
Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831-839. doi:10.1016/S0140-6736(19)31773-8 DOI: https://doi.org/10.1016/S0140-6736(19)31773-8
Lebwohl MG, Carvalho A, Asahina A, Zhang J, Fazeli MS, Kasireddy E, et al. Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2025;15(7):1633-1656. doi:10.1007/s13555-025-01423-0 DOI: https://doi.org/10.1007/s13555-025-01423-0
Thomas SE, Barenbrug L, Hannink G, Seyger MM, de Jong EM, van den Reek JM. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. Drugs. 2024;84(5):565-578. doi:10.1007/s40265-024-02028-1 DOI: https://doi.org/10.1007/s40265-024-02028-1
Yu S, Huo AP, Wang YH, Wei JC. Interleukin-23 versus interleukin-17 inhibitors in preventing incidental psoriatic arthritis in patients with psoriasis: a real-world comparison from the TriNetX US Collaborative Network. BioDrugs. 2025;39(2):297-306. doi:10.1007/s40259-025-00705-5 DOI: https://doi.org/10.1007/s40259-025-00705-5
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773 DOI: https://doi.org/10.1056/NEJMoa1602773
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200-2211. doi:10.1016/S0140-6736(22)00688-2 DOI: https://doi.org/10.1016/S0140-6736(22)00688-2
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201-1214. doi:10.1056/NEJMoa1900750 DOI: https://doi.org/10.1056/NEJMoa1900750
D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. doi:10.1016/S0140-6736(22)00467-6 DOI: https://doi.org/10.1016/S0140-6736(22)00467-6
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031-2046. doi:10.1016/S0140-6736(22)00466-4 DOI: https://doi.org/10.1016/S0140-6736(22)00466-4
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease. N Engl J Med. 2024;391(3):213-223. doi:10.1056/NEJMoa2314585 DOI: https://doi.org/10.1056/NEJMoa2314585
Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, et al. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn’s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025;406(10501):358-375. doi:10.1016/S0140-6736(25)00681-6 DOI: https://doi.org/10.1016/S0140-6736(25)00681-6
Ferrante M, D’Haens G, Jairath V, Danese S, Chen M, Ghosh S, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404(10470):2423-2436. doi:10.1016/S0140-6736(24)01762-8 DOI: https://doi.org/10.1016/S0140-6736(24)01762-8
D’Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940 DOI: https://doi.org/10.1056/NEJMoa2207940
Sands BE, D’Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, et al. Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2025;31(7):1876-1890. doi:10.1093/ibd/izae253 DOI: https://doi.org/10.1093/ibd/izae253
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405(10472):33-49. doi:10.1016/S0140-6736(24)01927-5 DOI: https://doi.org/10.1016/S0140-6736(24)01927-5
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, et al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA. 2024;332(11):881-897. doi:10.1001/jama.2024.12414 DOI: https://doi.org/10.1001/jama.2024.8819
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307-320. doi:10.1016/S2468-1253(22)00427-7 DOI: https://doi.org/10.1016/S2468-1253(22)00427-7
Desai P, Branigan P, Richards D, Vetter M, Cua D, Freeman T. Differential and combinatorial mechanism of action of golimumab and guselkumab in ulcerative colitis induction therapy: IL-23 blockade drives restoration of normal epithelium and mucosal healing. The American Journal of Gastroenterology 117(10S):p e527, October 2022. doi: 10.14309/01.ajg.0000902200.99170.8c DOI: https://doi.org/10.14309/01.ajg.0000902200.99170.8c
Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, et al. Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis. Gastroenterology. 2024;167(7):1460-1482. doi:10.1053/j.gastro.2024.07.046 DOI: https://doi.org/10.1053/j.gastro.2024.07.046
Janssen-Cilag Ltd. A study of guselkumab in participants with fistulizing, perianal Crohn’s disease (FUZION CD). ClinicalTrials.gov Identifier: NCT05347095. [updated September 12, 2025, accessed September 9, 2025] Available from: https://www.clinicaltrials.gov/study/NCT05347095#study-overview.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
